Streetbeat News

Revenues

CAKE

Analyst ratings for Cheesecake Factory (NASDAQ:CAKE) show a mix of opinions, with recent updates indicating a shift towards a more positive outlook. The average 12-month price target has increased to $35.75, up from $32.50, with analysts from Piper Sandler, Barclays, Wedbush, and JP Morgan adjusting their ratings and price targets. Cheesecake Factory's financial performance is highlighted by a revenue growth rate of 5.89%, a net margin of 2.16%, an ROE of 5.54%, and an ROA of 0.65%, despite a high debt-to-equity ratio of 5.79.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 7:00 pm

DHI

ITB

LEN

TOL

The U.S. housing market shows signs of recovery as existing home sales jump in January, with Toll Brothers Inc reporting strong results. Despite a slump in 2023 due to high mortgage rates, sales improved in the final quarter. The National Association of Realtors reported a rise in home sales to an annual rate of four million in January. However, mortgage applications fell by 10.6% in the week ending Feb. 16, as mortgage rates began to rise again. Shares of Toll Brothers, D.R. Horton Inc, Lennar Corporation, and the iShares U.S. Home Construction ETF saw gains.

Portfolio Pulse from Neil Dennis

February 22, 2024 | 6:37 pm

MNPR

Monopar Therapeutics Inc (NASDAQ:MNPR) shares surged 67.30% to $0.95 on high volume after announcing promising preclinical data for its MNPR-101 radiopharmaceutical program targeting cancers. The program showed significant tumor uptake and near-complete tumor elimination with a single injection. Additionally, Monopar received clearance in Australia to commence a Phase 1 trial of MNPR-101-Zr in patients with advanced cancers.

Portfolio Pulse from Vandana Singh

February 22, 2024 | 6:02 pm

CCRN

Cross Country Healthcare (NASDAQ:CCRN) has received mixed analyst ratings over the past quarter, with recent evaluations adjusting price targets and ratings due to changing market dynamics and company performance. The average 12-month price target is now $21.25, a 15.0% decrease from the previous $25.00. Analysts from Truist Securities, Benchmark, UBS, and Barrington Research have adjusted their ratings and price targets, reflecting concerns over the company's revenue decline of -30.47% as of September 30, 2023, and operational challenges. Despite this, CCRN's net margin and ROE outperform industry benchmarks, indicating efficient cost management and financial health.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:00 pm

RYTM

Analyst sentiment towards Rhythm Pharmaceuticals (NASDAQ:RYTM) has been predominantly bullish over the past three months, with a notable increase in the 12-month price target to $49.89, reflecting a 26.53% rise from the previous target. The company, engaged in developing therapies for rare diseases, has shown significant revenue growth and a strong market presence, despite challenges in ROE and ROA.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 6:00 pm

MCD

McDonald's expects the ongoing Middle East war to continue negatively impacting its systemwide sales and revenue, as disclosed in a recent SEC filing.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 5:37 pm

DPRO

GBNH

LRHC

MNPR

RIVN

ROOT

U.S. stocks traded higher with the Nasdaq Composite up by 300 points. The Dow and S&P 500 also saw gains. U.S. jobless claims fell to 201,000, below market estimates. La Rosa Holdings, Root Inc., and Monopar Therapeutics saw significant stock price increases following positive news, while Draganfly, Greenbrook TMS, and Rivian Automotive experienced declines. Crude oil prices rose by 1.1%, and the U.S. housing market showed improvement with a 3.1% increase in existing-home sales.

Portfolio Pulse from Avi Kapoor

February 22, 2024 | 5:11 pm

IFF

Analyst ratings for Intl Flavors & Fragrances (IFF) show diverse opinions with a recent shift towards more positive evaluations. Over the last three months, 11 analysts have provided ratings, with a notable increase in the average 12-month price target to $85.73, up 8.52% from $79.00. Recent actions include both upgrades and downgrades, reflecting dynamic market conditions and company performance. Despite the positive analyst sentiment, IFF faces financial challenges, including a -4.15% decline in revenue growth and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:00 pm

NPCE

NeuroPace (NASDAQ:NPCE) has been evaluated by 4 analysts over the last three months, showing a diverse range of opinions. The average 12-month price target for NPCE is now $14.75, up from $9.67, indicating a positive outlook. The company, focusing on medical devices for epilepsy, reported a 47.23% revenue growth and a net margin of -44.18%. Despite a high debt-to-equity ratio of 4.38, its market capitalization and revenue growth surpass industry averages.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:00 pm

CE

Analyst ratings for Celanese (NYSE:CE) show varied perspectives, with recent adjustments reflecting a generally positive outlook. The average 12-month price target has increased to $162.5, up 11.63% from $145.57, indicating bullish sentiment. Despite a negative revenue trend of -5.66% as of December 31, 2023, Celanese's financial health remains strong with a high net margin of 27.17% and ROE of 10.28%. The company's debt-to-equity ratio of 1.98 suggests higher financial risk.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:00 pm